These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 39012618)

  • 1. Clinical Pharmacokinetics and Pharmacodynamics of Letermovir in Allogenic Hematopoietic Cell Transplantation.
    Suetsugu K; Shigematsu T; Nakamura T; Hirota T; Ieiri I
    Clin Pharmacokinet; 2024 Jul; 63(7):945-964. PubMed ID: 39012618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic drug evaluation of letermovir prophylaxis for cytomegalovirus in hematopoietic stem cell transplantation.
    Deleenheer B; Spriet I; Maertens J
    Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1197-1207. PubMed ID: 30479172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Safety and Effectiveness of Letermovir in Patients Undergoing Allogenic Hematopoietic Stem Cell Transplantation: Final Results of Post-Marketing Surveillance in Japan.
    Fukuda M; Hattori J; Ohkubo R; Watanabe A; Maekawa S
    Clin Drug Investig; 2024 Jul; 44(7):527-540. PubMed ID: 38935253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Letermovir for prophylaxis of cytomegalovirus in allogeneic hematopoietic stem cell recipients.
    Cho JC; Le AD; Locke SC
    Drugs Today (Barc); 2018 Jun; 54(6):361-368. PubMed ID: 29998227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetics of letermovir following oral and intravenous administration in healthy participants and allogeneic hematopoietic cell transplantation recipients.
    Prohn M; Viberg A; Zhang D; Dykstra K; Davis C; Macha S; Sabato P; de Alwis D; Iwamoto M; Fancourt C; Cho CR
    CPT Pharmacometrics Syst Pharmacol; 2021 Mar; 10(3):255-267. PubMed ID: 33440077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exposure-Response Analyses of Letermovir Following Oral and Intravenous Administration in Allogeneic Hematopoietic Cell Transplantation Recipients.
    Prohn M; Cho CR; Viberg A; Dykstra K; Davis C; Sabato P; Stone J; Badshah C; Murata Y; Leavitt R; Fancourt C; Macha S
    Clin Pharmacol Ther; 2022 Feb; 111(2):485-495. PubMed ID: 34674258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: Real-world experience.
    Lin A; Maloy M; Su Y; Bhatt V; DeRespiris L; Griffin M; Lau C; Proli A; Barker J; Shaffer B; Giralt SA; Jakubowski AA; Papadopoulos EB; Papanicolaou GA; Seo SK; Perales MA
    Transpl Infect Dis; 2019 Dec; 21(6):e13187. PubMed ID: 31585500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation.
    Chemaly RF; Ullmann AJ; Stoelben S; Richard MP; Bornhäuser M; Groth C; Einsele H; Silverman M; Mullane KM; Brown J; Nowak H; Kölling K; Stobernack HP; Lischka P; Zimmermann H; Rübsamen-Schaeff H; Champlin RE; Ehninger G;
    N Engl J Med; 2014 May; 370(19):1781-9. PubMed ID: 24806159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and safety of the anti-human cytomegalovirus drug letermovir in subjects with hepatic impairment.
    Kropeit D; McCormick D; Erb-Zohar K; Moiseev VS; Kobalava ZD; Stobernack HP; Zimmermann H; Rübsamen-Schaeff H
    Br J Clin Pharmacol; 2017 Dec; 83(12):2678-2686. PubMed ID: 28722153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PBPK Modeling Strategy for Predicting Complex Drug Interactions of Letermovir as a Perpetrator in Support of Product Labeling.
    Wang YH; Chen D; Hartmann G; Cho CR; Menzel K
    Clin Pharmacol Ther; 2019 Feb; 105(2):515-523. PubMed ID: 29901213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and Tolerability of Letermovir Coadministered With Azole Antifungals (Posaconazole or Voriconazole) in Healthy Subjects.
    Marshall WL; McCrea JB; Macha S; Menzel K; Liu F; van Schanke A; de Haes JIU; Hussaini A; Jordan HR; Drexel M; Kantesaria BS; Tsai C; Cho CR; Hulskotte EGJ; Butterton JR; Iwamoto M
    J Clin Pharmacol; 2018 Jul; 58(7):897-904. PubMed ID: 29578577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of letermovir for prevention of cytomegalovirus infection after allogeneic haematopoietic stem cell transplantation.
    Razonable RR
    Curr Opin Infect Dis; 2018 Aug; 31(4):286-291. PubMed ID: 29746444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absorption, Metabolism, Distribution, and Excretion of Letermovir.
    Menzel K; Kothare P; McCrea JB; Chu X; Kropeit D
    Curr Drug Metab; 2021; 22(10):784-794. PubMed ID: 33622223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient.
    Jung S; Michel M; Stamminger T; Michel D
    BMC Infect Dis; 2019 May; 19(1):388. PubMed ID: 31068147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation.
    Marty FM; Ljungman P; Chemaly RF; Maertens J; Dadwal SS; Duarte RF; Haider S; Ullmann AJ; Katayama Y; Brown J; Mullane KM; Boeckh M; Blumberg EA; Einsele H; Snydman DR; Kanda Y; DiNubile MJ; Teal VL; Wan H; Murata Y; Kartsonis NA; Leavitt RY; Badshah C
    N Engl J Med; 2017 Dec; 377(25):2433-2444. PubMed ID: 29211658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Letermovir for Secondary Prophylaxis of Cytomegalovirus Infection and Disease after Allogeneic Hematopoietic Cell Transplantation: Results from the French Compassionate Program.
    Robin C; Thiebaut A; Alain S; Sicre de Fontbrune F; Berceanu A; D'Aveni M; Ceballos P; Redjoul R; Nguyen-Quoc S; Bénard N; Pahlavan-Grumel G; Cordonnier C
    Biol Blood Marrow Transplant; 2020 May; 26(5):978-984. PubMed ID: 32035273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Letermovir for prophylaxis of cytomegalovirus manifestations in adult allogeneic hematopoietic stem cell transplant recipients.
    Hecke SV; Calcoen B; Lagrou K; Maertens J
    Future Microbiol; 2019 Feb; 14():175-184. PubMed ID: 30644320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Letermovir for the prevention of cytomegalovirus infection in adult cytomegalovirus-seropositive hematopoietic stem cell transplant recipients.
    Foolad F; Aitken SL; Chemaly RF
    Expert Rev Clin Pharmacol; 2018 Oct; 11(10):931-941. PubMed ID: 30004790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of letermovir prophylaxis in CMV reactivation and disease after allogenic hematopoietic cell transplantation: a real-world, observational study.
    Brusosa M; Ruiz S; Monge I; Solano MT; Rosiñol L; Esteve J; Carreras E; Marcos MÁ; Riu G; Carcelero E; Martinez C; Fernández-Avilés F; Rovira M; Suárez-Lledó M; Salas MQ
    Ann Hematol; 2024 Feb; 103(2):609-621. PubMed ID: 37957371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world experience with letermovir for cytomegalovirus-prophylaxis after allogeneic hematopoietic cell transplantation: A multi-centre observational study.
    Hopff SM; Wingen-Heimann SM; Classen AY; Blau IW; Bug G; Hebermehl C; Kraus S; Penack O; Rettig AR; Schmitt T; Steinbrunn T; Teschner D; Vehreschild MJGT; Wehr C; Vehreschild JJ
    J Infect; 2024 Aug; 89(2):106220. PubMed ID: 38960103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.